Zhu-bai formula (DrugBank: -)
1 disease| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 224 | Purpura nephritis | 1 |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT02878018 (ClinicalTrials.gov) | September 2016 | 17/8/2016 | Cohort Study on Traditional Chinese Medicine Diagnosis and Treatment of Children With Henoch-Schonlein Purpura Nephritis | Cohort Study on Traditional Chinese Medicine Diagnosis and Treatment of Children With Henoch-Schonlein Purpura Nephritis | Henoch-Schonlein Purpura Nephritis | Drug: Qi-Ji Shen-Kang formula; Zhu-Bai formula; Yu-Shen formula;Drug: angiotensin-converting enzyme (ACE) inhibitor; adrenergic receptor binder (ARB); adrenal cortical hormone; Tripterygium wilfordii polyglycosidium; immunosuppressant | Liaoning University of Traditional Chinese Medicine | First Hospital of China Medical University;Shengjing Hospital | Active, not recruiting | 5 Years | 18 Years | All | 600 | China |